B of A Securities Rates Merck (MRK) buy, $141 Price Target
Analyst Tim Anderson reaffirmed a buy rating on Merck & Co., Inc. on June 30, 2026, setting a price target of $141, a 9.73% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B of A Securities rated Merck & Co., Inc. ($MRK) "buy" with a $141 price target on June 30, 2026.
Since the rating, $MRK is up 0.3% after 1 week, up 1.0% after 1 month and up 14.2% to date (from the $127.75 close on Jun 30, 2026).
MRK
Merck & Co., Inc.
Key Points
- B of A Securities analyst Tim Anderson reiterated a buy rating on Merck & Co., Inc. (NYSE:MRK) with a $141 price target on June 30, 2026.
- B of A Securities's $141 price target implies 9.73% upside from Merck & Co., Inc.'s ($MRK) current $128.50 share price.
- The stock trades at $128.50, sitting below its 50-day moving average of $138.39 while remaining above its 200-day moving average of $120.70.
- Wall Street sentiment leans positive with a consensus buy recommendation and 26 analyst opinions pointing to a mean price target of $152.96.
Get $MRK trade alerts by text
We text you when insiders, Congress or big funds trade $MRK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Merck & Co., Inc. alert may contain errors. Disclosures
B of A Securities Reaffirms View on Merck Stock
On June 30, 2026, B of A Securities analyst Tim Anderson maintained a positive stance on Merck & Co., Inc. (NYSE:MRK), reiterating a buy rating and issuing a price target of $141.00. This update provides fresh perspective on how well the pharmaceutical giant's market price aligns with Wall Street expectations, especially as the share price hovers below some of its near-term trading milestones.
B of A Securities vs. the S&P 500
Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.
$MRK price target
Merck & Co., Inc. daily closes and this analyst's $141 target. Not advice.
Merck Stock Trades Around $128 Following Analyst Update
Shares of Merck changed hands at $128.50, occupying a spot between key technical levels. The share price sits below its 50-day moving average of $138.39, yet it remains ahead of its longer-term 200-day moving average of $120.70. The broader 52-week trading window shows a low of $77.58 and a high of $156.92. The company carries a market capitalization of $368.84 billion alongside a forward P/E ratio of 15.65.
Recent Earnings and Financial Metrics
For the period, Merck reported total revenue of $66.57 billion, showing a revenue growth rate of 5.1%. The drug maker posted a net margin of 4.77% and a return on equity of 6.96%, with earnings per share landing at $1.25. Shareholders are looking ahead to October 29, 2026, when the healthcare company is scheduled to release its next round of financial results.
Dividend Profile for Shareholders
Merck distributes an annual dividend rate of $3.40 per share, which translates to a dividend yield of 2.31%. The company maintains a dividend payout ratio of 2.69, returning steady cash to investors while funding ongoing research and development.
Wall Street Analyst Coverage and Consensus
Other major financial institutions have also updated their outlooks on the stock in recent months. Citigroup maintained a neutral rating on October 12, 2026, adjusting its price target to $145.00 from $125.00. RBC Capital kept a sector perform rating with a $145.00 target on October 12, 2026. Cantor Fitzgerald maintained a neutral rating on October 8, 2026, setting a target of $145.00. Morgan Stanley kept an overweight rating on October 7, 2026, with a target of $177.00. JP Morgan maintained an overweight rating on October 5, 2026, with a $165.00 target. Scotiabank maintained a sector outperform rating on September 29, 2026, raising its target to $180.00. HSBC maintained a buy rating on September 10, 2026, with a target of $172.00, while Leerink Partners maintained an outperform rating on September 9, 2026, with a target of $161.00. Overall, the stock carries a consensus buy recommendation from 26 analysts who share an average price target of $152.96.
Inside Merck's Global Operations
Headquartered in Rahway, New Jersey, Merck & Co. operates as a global healthcare company with 73,000 employees. The firm discovers, develops, and delivers human health pharmaceuticals across oncology, vaccines, and specialty care under well-known brands like Keytruda and Gardasil, alongside an extensive veterinary medicine portfolio.
What to Watch Next for Merck
Investors will keep an eye on how the equity behaves relative to Anderson's $141.00 target and the broader analyst consensus of $152.96 ahead of the late October earnings report. Market participants should monitor upcoming filing updates and clinical trial progress to gauge future momentum.
Related Filing Alerts
Source: B of A Securities's rating change on $MRK (Jun 30, 2026). Written by software, not financial advice. How we make alerts